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Summary
Objectives: Evaluation of immune profiles in human breast
cancer using high-sensitivity detection and analysis methods.
Design: Cohort comparative analysis studies of breast
tissue.
Setting: Human hospital and laboratory healthcare
facilities.
Participants: Women over 18 years.
Main outcome measures: Evaluation of the comparative
immunophenotype of human breast carcinoma and normal
breast tissues.
Results: Leukocyte density and specific subgroups of
lymphocytes and macrophages were generally higher in
breast cancers compared to normal breast tissues. CD3,
CD4, CD45RO, CD45RA(2H4), CD45 and HLA Class II
(on TIL) were significantly expressed on breast tumour
tissues compared with normal tissues (p< .01). Some
30% of T-cells were gd-TCR positive, but the majority
were ab-TCR in type. CD19 (B-cell), CD14 (FMC32 and
33) and HLA Class I levels (epithelial and TIL) showed no
significant differences. IL-2a receptor expression was low
or absent on most TIL.
Conclusions: High-sensitivity and image analysis techniques
permitted accurate characterisation of the TIL infiltrate for
immune profiling. Breast carcinoma showed predominance
of CD4 T-cells of mainly memory phenotype. Normal
breast tissues showed low leukocyte infiltration. Further
correlation of these findings with clinical outcome, includ-
ing survival, is proceeding with encouraging results.
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Introduction
Leukocytes are consistently associated with human
breast carcinomas. T-cells represent the predominant
cell type within inﬁltrating leukocyte/lymphocyte
(TIL) populations.1–4 An increased density of TILs
in breast cancer appears broadly associated with
improved survival following surgical resection of the
tumour,5–9 has been additionally associated with
improved response to adjuvant and neo-adjuvant
chemo-radiotherapy,10–13 and has also recently asso-
ciated with PD-1/PDL-1 expression.14
The speciﬁc lymphocytic phenotype has been less
clearly deﬁned. Both CD8þ cytotoxic T-cells and
CD4þ helper T-cells are widely considered to protect
against oncogenesis,15–17 while recent data indicate
that CD4þCD25þ regulatory T-cells may actually
suppress the antitumoral immunological response.18
Other authors have found that increased expression
of CD3þ has been associated with improved treat-
ment response.19,20 The precise qualitative details
of the nature of the inﬁltrate have been complex
to understand, and some disparity remains within
the literature regarding the major subpopulations
within the lymphoid inﬁltrate in normal breast and
breast carcinoma tissues, particularly regarding the
predominance of CD4þ or CD8þ cells.15,16,21
The underlying causes of the variability regarding
the characterisation of TILs may partly reside in the
sensitivity of the detection methods used. Most studies
have used lower sensitivity, non-heavy metal enhanced
methods to identify the component cell types of the
inﬁltrate. Consequently, cells with surface molecules
in low copy number may not be demonstrated by
standard diaminobenzidine immunoperoxidase stain-
ing. However, at least a seven-fold greater detection
sensitivity for low copy number surface molecules can
be achieved using heavymetal enhancedDABmethods
to reveal greater numbers of positive cells than unen-
hanced DAB staining.22,23
Another perhaps even more crucial reason for the
considerable variation in the ﬁndings of past studies
resides in techniques used for quantitation of cellular
immunophenotypes. Traditionally, manually graded
microscopic quantitation methods have been used
almost universally to measure and compare results.
Slides of tissue sections are assigned a representative
grade of density on a discontinuous ordinal scale such
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as 0, þ/, þ, þþ, þþþ and þþþþ. Considerable
intra- and interobserver errors exist within standard
light microscopic direct manual quantitation meth-
ods.24–26 Video image analysis systems have provided
amore standardised andobjectivemethodof cell quan-
titation, although manual quantitation still remains
the standard methodology used. Comparison of
mononuclear inﬁltrates fromdiﬀerent tumours is how-
ever an onerous and imprecise task using direct visual
methods.27 Therefore, the novel technique of compu-
ter-assisted video image analysis, previously reported
by Coventry et al.,28 oﬀers an approach towards quan-
titation of cellular inﬁltrate within breast cancer with
better standardisation and reproducibility.
If the immunophenotype could be accurately
determined in breast cancers, then the association
with longer term survival could potentially be more
reliably evaluated.
The aim of the present study was to use monoclo-
nal antibody immunostaining with higher sensitivity
nickel-enhanced DAB immunochemistry and com-
pare both standard manual visual quantitation and
video image analysis quantitation methods to deﬁne
the immune proﬁle (major TIL subpopulations) of
normal breast and breast carcinoma tissues, including
the relative balance of CD4þ or CD8þcells.
Methods
The immunostaining and analysis methodology for
this study was described previously in Coventry et al.28
Preparation and immunostaining of breast tissues
Comparison was made between 25 primary breast car-
cinoma and 10 histologically normal tissue samples
taken directly following surgical resection, immedi-
ately cryopreserved and then sectioned according to
protocol. The samples were taken from surgical speci-
mens by the attending pathologist during surgical
pathology dissection at Flinders Medical Centre and
Flinders University, Adelaide. Investigators were not
involved in the surgery or pathology reporting. Studies
were approved by the Institutional Human Research
Ethics Committee and data were deidentiﬁed for ana-
lysis and reporting. Samples were evaluated by inves-
tigators without knowledge of the pathology details to
avoid bias. Normal breast samples were taken from
breast reduction specimens and conﬁrmed non-malig-
nant breast tissues.
Monoclonal antibodies
Multiple primary murine antihumanmonoclonal anti-
bodies (Table 1) were used for staining. All were
incubated in a humid chamber overnight for adequate
binding and avoidance of drying. Each antibody was
titrated on human tonsil and lymph node sections for
optimum dilution before application on breast sec-
tions, to obtain high contrast from background.
Negative isotypic control antibodies and relevant posi-
tive control tissues were included.
Immunostaining
Horse antimouse biotinylated second antibody was
incubated for 30minutes, with endogenous peroxidase
blocking using a 1% solution of H2O2 in 70% ethanol.
Avidin–biotin immunoperoxidase complex was incu-
bated for 45 minutes using Vectastain kit reagents
(Vector Laboratories, Burlingame, CA).
Importantly, 3,30-diaminobenzidine (Sigma, St Louis,
MO) enhancedwith 0.08%nickel chloridewas used for
higher sensitivity. Three ﬁve-minute phosphate-buf-
fered saline washes between steps ensured adequate
removal of non-bound antibodies and reagents.
Direct microscopic visual quantitation
The stained tissue sections were scored on a grading
system of 0, þ/, þ, þþ, þþþ or þþþþ by three
independent observers (BJC, JB, JMS) to evaluate aver-
age density of cells per unit area of section at250mag-
niﬁcation. The results of the 25 breast carcinoma and 10
normal breast tissue samples were analysed for the
degree of cellular inﬁltrate for each antibody. A grade
was assigned for each tissue, both normal and tumour,
and then recorded.
Computer-assisted video image analysis
quantitation
Twenty of the stained tissue sections were examined
for quantitation using video image analysis, as previ-
ously described.28 Brieﬂy, a microscope head-
mounted video camera captured serial images across
an immunostained tissue section. Thresholds were
chosen to detect reaction product, and total pixel
density measurements were made after background
correction.28 Data sets for each consecutive video
ﬁeld were made, and graphs were plotted for each
tissue section scanned using Statgraphics time-series
analysis (version 4.0; Statpoint Technologies,
Warrenton, VA).
Statistics
Statistical analyses were performed using SAS version
9.2 (SAS Institute Inc., Cary, NC) and SPSS
Statistics version 20 (IBM, Armonk, NY).
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Results
Descriptive statistics
The patient and tumour characteristics are detailed in
Table 2. A total of 25 patients were included in the
study, with a median age of 61 years (range 31–85).
The histology from the vast majority of patients (20;
80%) were of the invasive ductal tumour type (not
otherwise speciﬁed), with 5 (20%) demonstrating
each of undiﬀerentiated (1), invasive lobular (2),
medullary (1) and mixed invasive ductal/lobular
tumour (1). Eleven patients (44%) were reported as
having poorly diﬀerentiated (high-grade) tumours, 11
being moderately diﬀerentiated (intermediate-grade),
2 as well diﬀerentiated (low-grade) and 1 not deﬁned.
The mean tumour size was 34.7mm (range 14–
190mm). Fourteen patients (56%) of the cohort
were lymph node positive. Regarding TNM staging,
7 (28%) were classed as being TNM Stage I, with 12
(48%) being Stage II, 4 (16%) were Stage III and 2
were not available.
Direct visual quantitation
The frequency percentage of visual grades assigned
for the 25 breast carcinoma and 10 normal breast
tissue samples tissues were represented on histograms
(Figure 1) displaying each grade of cellular inﬁltrate
for each speciﬁc monoclonal antibody.
Normal breast tissues. Low numbers of lymphocytes
were present in within normal breast tissue. T-cells
predominated with a T4:T8 ratio of 1 and an equal
proportion of naive CD45RA to memory CD45RO
cells. Most of the T-cells were ab-TCR in type with
Table 1. Monoclonal antibodies used.
MoAb Antigen Subclass Concentration Source
Leu 4 CD3 IgG1 1/50 BD
DakoT4 CD4 IgG1 1/20 Dakopatts
Leu 2a CD8 IgG1 1/50 BD
UCHL1 CD45Ro IgG2a 1/100 Beverley
FMC44 CD45Ra IgG1 S/N Zola
FMC51 CD45R IgG1 1/05 Zola
aTac CD25 IgG1 1/25 BD
4F2 CD98 IgG2a 1/40 BD
2H4 CD45Ra IgG1 1/100 Coulter
dT dTCR IgG1 1/400 Brenner
bF1 bTCR IgG1 1/10 T-cell Sci
FMC14 HLA-D IgG1 S/N Zola
FMC63 CD19/21 IgG1 1/50 Zola
FMC32 CD14 IgG1 1/10 Zola
FMC33 CD14 IgG1 S/N Zola
Leu 19 CD16 IgG1 1/10 BD
Leu 7 CD57 IgM 1/10 BD
Leu 22 CD43 IgG1 1/200 BD
Leu 23 CD69 IgG1 1/10 BD
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approximately 10% or less being gd-TCR positive.
Very small numbers of B-cells, CD16 positive cells
and macrophages were located interstitially between
the breast ducts. Most of the mononuclear cells in
normal breast tissues were IL2a receptor negative,
but HLA-D and HLA-DQ positive. The duct
epithelium expressed moderate levels of HLA-D in
about half the cases examined. HLA-Class I (b2-
microglobulin) was expressed at moderate levels on
normal breast duct epithelium examined.
A novel ﬁnding was that some gd-T cells were pre-
sent in an intraepithelial location in the ducts of
Table 2. Patient and primary breast tumour details.
Age Lymph node status Tumour type Tumour size (mm) TNM stage Differentiation
85 þ (4/10) ID 35 II Mod.
61 þ (4/15) ID 18 II Well
53  (0/15) ID 25 II Poor
79 þ (1/1) ID 25 III Poor
46 þ (2/7) ID 15 II Poor
53 þ(19/20) ID 30 II Poor
53  (0/11) ID 15 I Mod.
68 NA IL 15 NA Mod.
45  (0/13) ID 15 I Poor
41 þ (2/14) ID/IL 29 II Mod.
48  (0/6) ID 30 I Poor
62  (0/14) ID 14 I Mod.
55  (0/6) ID 75 III Mod.
58 þ (18/18) ID NA III Poor
62 þ (4/9) ID 22 II Mod.
63  (0/7) ID 28 I Mod.
68  (0/15) ID 18 I Poor
82 þ (5/7) ID 35 III Poor
68 þ (2/17) ID 75 II Mod.
31 þ (1/6) UD 190 II Poor
52 NA NA NA NA NA
71 þ (2/6) ID 30 II Mod.
68 þ (3/10) M 30 II Poor
80  (0/10) ID 15 I Well
39 þ (5/14) ID 15 II Mod.
ID: infiltrating ductal; IL: infiltrating lobular; M: medullary; Mod.¼moderately differentiated; NA¼ not available/reported; UD: undifferentiated;
þ¼ tumour involved lymph node(s); ¼ non-tumour involved lymph node(s); (x/y)¼ no. of positive nodes (x) out of the total examined (y).
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normal breast tissue (Figure 2(a)). Double immunos-
taining with IgA monoclonal antibodies showed these
gd-T cells to be associated with, but separate from,
IgA producing cells (Figure 2(b))
Breast carcinoma tissues. The mononuclear inﬁltrate in
breast carcinoma contained mainly T-cells, which
were present in much larger numbers than in the
normal tissues. There was a predominance of CD4
cells (T4:T8 ratio of >1; signiﬁcant) and a predomin-
ance of memory CD45RO cells over naive CD45RA
cells (not statistically signiﬁcant). No statistically sig-
niﬁcant diﬀerence was found between the grading of
CD3 positive cells and CD4 cells in the tumour inﬁl-
trates (p¼ .978), but CD4 and CD8 cell gradings were
highly statistically signiﬁcantly diﬀerent (p< 0.001).
The proportion of T-cells that were gd-TCR positive
was 30%, with the majority of cells constituting ab-
TCR in type. IL-2a receptor expression was low or
absent on TIL in all but three tumours, and HLA-D
was expressed heavily on TIL in all but one tumour.
HLA-DQwas expressed on almost all TIL at moderate
to high levels. HLA-Dwas expressed on tumour cells at
low levels in approximately 25% of tumours tested,
whereas HLA Class I was expressed on tumour cells
at moderate to high levels in 70% of tumours.
Low numbers of B-cells and CD16 positive cells
were present. Macrophages were present in tumours
in a greater proportion than in normal breast tissues.
Notably, CD45 labelled more cells than were appar-
ently accounted for by all cells labelled by T, B, CD16
and macrophage antibodies.
Figure 1. Histograms comparing manual visual grades of infiltrate found in normal breast and primary breast carcinoma tissues
with respect to immunostaining for various antigens.
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When breast tumour tissues were compared with
normal tissues, the excess numbers of CD3, CD4,
CD45RO, CD45RA(2H4), CD45 and HLA Class II
(on TIL) were statistically signiﬁcant (p< .01,
Kolmogorov–Smirnov). CD19 (B-cell), CD14
(FMC32 & 33) and HLA Class I levels (epithelial and
TIL) showed no statistically signiﬁcant diﬀerences.
Video image analysis
The results from VIA assessment of the same immu-
noperoxidase-stained tissue sections used for the
direct visual quantitation data above are depicted in
Figure 3. Results for the average area under each of
the CD3 curves and direct visual grades for each
case have previously been published.28 Data in
Table 3 depict the VIA pixel measurements in
ascending order of magnitude for the 20 individual
breast cancer specimens stained with CD3, with the
corresponding ordinal grade measured by manual
visual method for each particular tumour shown
alongside.
Associations between VIA pixel values and age/
tumour size
Associations between pixel values and both age (in
years)/tumour size (diameter in millimetre) were
assessed using Pearson correlation coeﬃcients.
Table 4 shows that VIA pixel values were signiﬁcantly
Figure 1. Continued.
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correlated with tumour size, whereas the correlation
between VIA pixel values and age approached
signiﬁcance.
Associations between VIA pixel values and lymph
node status, TNM stage and differentiation as
assessed using independent samples t-Tests
Table 5 shows no evidence for a signiﬁcant diﬀerence
in mean VIA pixel values between lymph node nega-
tive and lymph node positive patients (t18¼ 0.060,
p¼ 0.56). Similarly, no evidence was found for a stat-
istical diﬀerence in mean VIA pixel values between
TNM Stage I and Stage II/III patients (t18¼ 0.070,
p¼ 0.49). Last, no statistical diﬀerence was evident
between mean VIA pixel values for patients with
well to moderately diﬀerentiated compared to poorly
diﬀerentiated breast tumours (t18¼0.075, p¼ .46).
Discussion
Detailed immune proﬁles of breast carcinomas and
normal breast tissues were reported in this study,
which is of increased relevance given the current
interest in immunotherapeutic approaches to breast
cancer management.29,30 The most sensitive tech-
niques were used to obtain a detailed analysis of
major subpopulations within the lymphoid inﬁltrate
in breast carcinoma and normal breast tissues. By
combining high-sensitivity, heavy metal enhanced
di-aminobenzidine immunoperoxidase staining meth-
ods with computer-assisted video image analysis for
cell quantitation, the most accurate evaluation was
Figure 1. Continued.
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possible, and this was compared with standard
manual visual quantitation.
This revealed several major qualitative and quan-
titative diﬀerences in the cellular inﬁltrates of both
normal and malignant breast tissues. T-lymphocytes
were present in very low numbers around breast ducts
in normal tissues but were present in large numbers
within and around breast carcinomas. Some 90% of
tumours were shown to have inﬁltrates of þþ or
greater compared to 20% for normal breast tissues.
Most of the T-cells were CD45RO indicating previ-
ous antigen priming31 and the proportion of CD4
cells was greater in tumours. The proportion of gd-
TCR positive cells was also greater in tumour tissues,
perhaps suggesting less speciﬁc T-cell mechanisms
might also be operational in the tumour microenvir-
onment. An observation which might also support
this notion were the increased macrophage numbers
associated with tumour tissue compared to normal
tissues, with over 75% of tumour samples having a
þþ or greater inﬁltrate compared to 12% for normal
tissues. B-lymphocytes were slightly increased in
tumour tissues over normal tissues, but the B-cell
inﬁltrate was sparse even in tumours. Similarly,
sparse inﬁltration of CD57 positive cells (neutrophils)
was noted in both tumours and normal tissues.
Collectively, these results show that tumour tissues
possess a clearly diﬀerent leukocyte inﬁltrate to
normal breast tissues. Quantitative diﬀerences were
present in T-cell and macrophage numbers; in add-
ition, qualitative diﬀerences were found. CD4 to CD8
Figure 1. Continued.
Figure 2. (a) High-sensitivity staining showing a gd-T cell
in an intraepithelial location between ductal cells of normal
breast tissue. (b) Intraepithelial gd-T cell shown associated
with IgA-producing cells using double staining with IgA
monoclonal antibodies.
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subgroup proportions, d-TCR positive cells and
CD45RO positive cells were all elevated in tumours.
These ﬁndings suggest that T-cells, and to a lesser
extent macrophages, either proliferate or are
attracted to the tumour microenvironment to aggre-
gate in considerable numbers in most of the breast
tumours examined. Most of these cells display the
180,000 kDa form of the leukocyte common antigen
implying previous antigen priming and cellular acti-
vation.32 Expression of the CD25 molecule as a
marker of early activation was very low in normal
breast tissue and also low in the inﬁltrating cell popu-
lation associated with breast tumours, supporting
other studies.33,34 CD4 cells appeared to predominate
over CD8 cells in the breast tumours tested.
T-cells consisting of mainly ab-TCR CD4 cells
comprise the major component of the tumour inﬁl-
trate of breast tumours, and possess the CD45RO
phenotype, are HLA class II positive in 95% of
tumours examined and show almost uniform absence
or very low expression of the p55 and p70 chains of
the IL-2R. Taken together, these ﬁndings suggest that
the lymphocytes have been exposed to antigen, but
are not activated, being down-regulated. Considering
the data from VIA quantitation of immunostained
cells from the same tumour sections as used for
direct visual assessment, several features are appar-
ent. Clustering of CD3 cells within the tumour is not-
able from the proﬁles, and considerable variations are
observed between the direct visual grade and the area
under the VIA curve. The limitations imposed by the
quantal nature of the direct visual grading method
become apparent from this comparison.
Novel VIA techniques appeared to be a useful tool
that allows for quantitatively correlating staining
density as a continuous variable with various patient
characteristics. Such analysis has often been diﬃcult
previously. Staining density was shown to correlate
positively with tumour size, but no association was
found with lymph node status, TNM stage or degree
of diﬀerentiation. This is likely due to the small
sample size, although one of the potential beneﬁts
of VIA is that larger studies can be conducted more
easily, compared with time-intensive and slower
manual visual grading.
The VIA methods in this study also provided
graphical proﬁles for each of the diﬀerent antibodies.
This allowed more detailed representation of the pat-
tern of distribution of the subpopulations of lymph-
oid inﬁltrate within the tumour. Features such as
clustering of cell types can also be observed and
quantitated using VIA.28 Moreover, it also allowed
for the association comparison of areas within the
tumour where cellular subgroups could be identiﬁed
as either overlapping or distinct. Analysis of cytokine
expression and cytokine receptor expression within
the tumour microenvironment using these methods
is under current investigation.
Figure 3. Video image analysis graphical profiles for serial sections from five separate tumours immunoperoxidase stained using
various primary antibodies for comparison with direct visual quantitation data in Figure 1. Vertical axis is density of staining;
Horizontal axis is distance across the tissue section.28 Axes are the same for all graphs shown.
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Our previous work demonstrated that both den-
dritic cell number and activation were low in human
breast cancers and showed an association between
density of CD1a cells and ﬁve-year survival, although
non-signiﬁcant at the p¼ .05 level.35,36
The importance of the current ﬁndings and tech-
niques used in this study are that better under-
standing of the distribution of the tumour
inﬁltrating leukocyte population within human
breast carcinomas is now possible. Further work
is revealing the implications of TIL characteristics
for clinical outcome, including longer term sur-
vival, which is currently being actively evaluated
in greater detail.
Conclusion
The results obtained in this study indicate that
although primed T-cells predominate, other immuno-
logical cell types are present. These other cell types
and the relationship to the structural morphology
and interaction with CD3 cells require further investi-
gation. Indeed, signiﬁcant interaction or cooperation
between cell types in the tumour inﬂammatory inﬁl-
trate likely does occur. More detailed analysis of the
distribution of immunological cells within the TIL
inﬁltrate using high-sensitivity immunostaining and
VIA techniques oﬀers a logical approach recom-
mended for further investigations in this area. The
potential importance and signiﬁcance of these ﬁnd-
ings lie in the association between breast cancer TIL
immune proﬁle and clinical outcome, including
survival.
Table 3. Comparison of VIA pixel value with assigned manual
visual grade.





















Table 4. VIA pixel density correlated with patient age and
tumour size.
Age Tumour size
VIA pixel density r¼0.42 r¼ 0.45
p¼ 0.067 p¼ 0.048
Pearson correlation coefficients; n¼ 20.
Table 5. VIA pixel density correlated with lymph node
status, TNM stage and tumour differentiation.
VIA pixel density and lymph node status
Lymph node status Number Mean Standard
deviation
Negative 8 18,065.00 13,540.5
Positive 12 14,044.30 15,514.5
VIA pixel density and TNM stage
TNM stage Number Mean Standard
deviation
I 7 18,795.90 14,454.0
II/III 13 13,960.00 14,857.1
VIA pixel density and tumour differentiation
Differentiation Number Mean Standard
deviation
Moderate/well 11 13,416.90 13,596.5
Poor 9 18,385.00 15,960.5
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